Biogen Inc.

BIIB · NASDAQ · USD

Analysis

Last 4 earnings calls · through Q2 FY2026

Biogen has stopped shrinking by buying growth: the Apellis medicines plus its own launches now out-earn the shrinking MS business, and revenue is guided up for the year. The cash goes out today; the trial results that justify it arrive over the next four quarters.How much of the Q2 revenue rise came from Apellis rather than Biogen's own drugs?

  • The new products now outsell Biogen's aging MS franchise.

    The growth portfolio passed $1 billion in Q2 FY2026, and after Apellis closed management flipped full-year revenue guidance from a decline to an increase. That reversal is the story: a company managing decline is now spending to grow.How fast is the MS franchise shrinking now that a TYSABRI copy is on the market?

  • Buying that growth cost earnings and added debt.

    Full-year EPS guidance fell by roughly $3 a share for deal and pipeline charges, and net debt jumped to about $6.8 billion. Management says Apellis starts adding to earnings in 2027, so the cash cost is certain today and the return is not.

  • The results that justify the spending arrive within a year.

    Five late-stage trial readouts land within four quarters, starting with lupus at the end of 2026, and two were pulled forward as enrolment ran fast. They either turn the pipeline into revenue or leave the debt without a payoff.What separation from placebo would Biogen need to call the lupus trial a win?

Bullish
  • Growth products overtake legacy MS
    The bull case is that the newer medicines now bring in more revenue than the multiple sclerosis franchise, so the top line can grow while the old drugs shrink.
  • Apellis adds marketed medicines
    Buying Apellis adds two medicines that are already being sold and that management expects to keep growing faster than the rest of the portfolio.
  • High-dose SPINRAZA conversion
    Converting patients to high-dose SPINRAZA is running ahead of expectations and is winning some patients back from the oral competitor.
Bearish
  • Multiple sclerosis base erodes
    The bear case is that generic fumarates and a TYSABRI biosimilar are shrinking the multiple sclerosis base faster than the new products replace it.
  • Debt taken on for Apellis
    The Apellis purchase was paid for largely with new borrowing, so a much larger debt load and its interest cost now sit against earnings.
  • Binary late-stage trial results
    A return to growth rests on trial results that are years from becoming sales, and a miss would leave a hole the current portfolio cannot fill.
See the full bull & bear case
PoliticiansInstitutionsInsiders
PoliticianTransactionAmountTradedFiled
Donald Trump
Republican · Executive
Sale≥$1KJun 12Aug 22
Donald Trump
Republican · Executive
Purchase≥$1KMay 11Jul 1
Maria Elvira Salazar
Republican · House · FL-27
Sale≥$1KSep 24Oct 7
Kevin Hern
Republican · House · OK-1
Sale≥$1KAug 18Sep 1
Alan Armstrong
Republican · Senate · OK
Purchase≥$1KMar 27Jul 21

Congressional trading data provided by QuiverQuant

See all
Product segmentsGeography
FY2025 · USD

How Biogen turned $9.9B of revenue into $1.9B of operating income.

Revenue
MS Product Revenues$4.0B▼ 7.15% YoY
TYSABRI product$1.7B▼ 2.89% YoY
SPINRAZA$1.5B▼ 1.68% YoY
Fumarate$1.4B▼ 10.57% YoY
Interferon$945.6M▼ 2.31% YoY
Total revenue$9.9B
Gross profit$7.5B75.7%
Operating income$1.9B19.0%
See all